Multi-color Mapping of Cancer Molecular Signatures and Tumor microenvironment
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R33CA235319-02S1
Grant search
Key facts
Disease
COVID-19Start & end year
20192022Known Financial Commitments (USD)
$80,860Funder
National Institutes of Health (NIH)Principal Investigator
Jenny J YangResearch Location
United States of AmericaLead Research Institution
Georgia State UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
AbstractSince the recent identification of a novel coronavirus from the pneumonia outbreak in Wuhan, China, now namedas SARS-CoV-2, the virus has spread globally very rapidly. SARS-CoV-2 is closely related to SARS-CoVemerged in 2003. While there are many factors associated the virus transmission, the pattern of SARS-CoV-2spread is distinctly different from that of SARS-CoV. Evidence shows that there is virus transmission beforeonset of symptoms in patients. Diagnosis of the virus infection is more difficult because the infection of SARS-CoV-2 may be in the lower respiratory track. This proposal takes advantage of our pioneered imaging platformand protein agents to rapid develop pMRI diagnostic imaging with strong translational potential in facilitatingeffective treatment to halt further chronic and pandemic lung disease progression. It is highly transformative andspecifically address the call of proposal for Urgent Supplement using existing imaging modality and MRI andlargely extended its capability. The developed MRI diagnostic imaging with its high resolution, non-radiative, andmuch improved sensitivity than current CT in clinical will significantly facilitate accurate detection of coronavirusinfection in patient and control of Covid-19 and other SARS-like COV infections.